Alpha-Galactosidase
1. Identity: Names, Classification, Sources, and Forms
1.1 Chemical and Systematic Identity
Alpha-galactosidase is an enzyme that catalyzes the hydrolysis of terminal α-galactosyl moieties in oligosaccharides and polysaccharides, aiding in the digestion of galacto-saccharides commonly found in plant-based foods. Its systematic Enzyme Commission designation is EC 3.2.1.22. Alpha-galactosidase is an enzyme that belongs to the glycoside hydrolase family. The enzyme is also written as α-galactosidase and, in the context of the human lysosomal form, as alpha-galactosidase A (abbreviated α-GAL A or AGAL), encoded by the GLA gene.
The enzyme performs the hydrolysis of terminal, non-reducing alpha-D-galactose residues from their parent molecules, acting like a molecular scissor specifically targeting and cutting the α-galactosidic linkage that connects a galactose sugar unit to the rest of the larger molecule. This targeted action distinguishes it from related enzymes like beta-galactosidase, which breaks the bond found in milk sugar (lactose). The specific bond broken by alpha-galactosidase is often an α-1,6-galactosyl unit, which is resistant to most human digestive enzymes.
1.2 Forms and Subtypes
Two functionally distinct forms of alpha-galactosidase are relevant to human health:
- Fungal/microbial alpha-galactosidase: An α-galactosidase preparation derived from the mold Aspergillus niger is used as a dietary supplement to improve digestion of oligosaccharides and reduce gas-related symptoms in individuals with complex carbohydrate intolerance, particularly after consumption of legumes.
- Human alpha-galactosidase A (α-GAL A): Human α-galactosidases encoded by GLA and MYORG genes share a conserved modular architecture built around a TIM barrel catalytic domain with additional β-sandwich accessory domains. The lysosomal enzyme α-galactosidase A (GLA product) is a secreted glycoprotein that forms a homodimer; each subunit contains an N-terminal TIM barrel harboring the active site and a C-terminal antiparallel β-sandwich, with multiple N-linked glycans that stabilize the fold and mediate lysosomal targeting via mannose 6-phosphate receptors.
It should be noted that the fungal Aspergillus niger aglA gene, originally annotated as an α-galactosidase, actually encodes an enzyme with predominant α-N-acetylgalactosaminidase activity. This fungal "α-galactosidase" is structurally and functionally most closely related to human α-N-acetylgalactosaminidase (NAGA, historically termed α-galactosidase B), not to human α-galactosidase A (GLA).
1.3 Natural and Industrial Sources
Alpha-galactosidase is a well-known enzyme involved in the hydrolysis of α-galactosides present in various important plants or plant parts used for nutritional purposes such as legumes, vegetables, grains, and cereals. Alpha-galactosidase enzymes are produced by various microorganisms, plants, and animals.
Fungal strains, including Mortierella vinacea, Circinella muscae, and Absidia griesola, were developed to produce alpha-galactosidase activity with low invertase activity. Commercially, alpha-galactosidase is produced through fermentation processes using specific fungi, particularly Aspergillus niger. The enzyme is then extracted, purified, and formulated into supplements that can withstand the acidic environment of the stomach to reach the intestines where they are needed most.
Alpha-galactosidase also occurs naturally in plant seeds. Treatment of raffinose with α-galactosidase (from green coffee beans) gives sucrose and galactose. The enzymatic treatment of sugar beet molasses is an industrial process, operated in the United States since the 1970s.
1.4 Commercial Preparations and Dosage Forms
Alpha-galactosidase supplements come primarily as enzyme preparations derived from microbial sources like Aspergillus niger or Saccharomyces cerevisiae, offering high stability and activity. Common forms include capsules, tablets, and chewables, often standardized by activity units such as 300–450 GalU (galactosidase units) per serving. It is frequently combined with other digestive enzymes like amylase, cellulase, and sucrase in broad-spectrum formulas for comprehensive carbohydrate digestion.
The most well-known commercial product (Beano) is available in various forms, including tablets, meltaways, and liquid drops. The standard tablet form typically contains 150 GalU (galactosidase units) of alpha-galactosidase enzyme per tablet. Activity is quantified in GalU — one GalU is the amount of galactosidase that releases 1 µmol of galactose from its substrate in one minute.
Most commercial supplements use alpha-galactosidase derived from Aspergillus niger. This fungal source is generally recognized as safe (GRAS) for food use.
2. Traditional and Historical Use
Alpha-galactosidase as an isolated compound was discovered and developed in the 20th century, particularly with the advancement of enzyme biotechnology. Its use in supplement form is entirely modern, with no direct equivalent in traditional herbal or folk medicine.
However, traditional medical systems were aware of the digestive difficulties caused by legumes and fibrous vegetables, and they developed culinary and herbal strategies to mitigate these effects. These traditional strategies — including soaking legumes, fermenting foods, and cooking with certain spices — represent indirect precursors to the modern understanding of oligosaccharide reduction.
Food processing techniques including soaking, germination, decortications, fermentation, cooking, and use of enzymes such as α-galactosidase can significantly increase the level of soluble dietary fiber fraction, reduce the levels of α-galactosides, and hence enhance the digestibility of the food.
Scientific interest in α-D-galactosidases dates to the identification of sources including brewer's yeast at the end of the 1800s. In 1990, a dietary supplement called Beano was developed based on the research regarding gas-causing vegetables; the product containing the enzyme from Aspergillus niger was commercialized as a digestive aid.
Alpha-galactosidase is produced industrially for applications in food and feed processing, as well as in dietary supplements. Alpha-galactosidases are an important group of enzymes used in food processing; the most important use of this group of enzymes is in soy-based foods, which have great nutritional relevance all over the world because of their high protein concentration.
3. Key Constituents and Mechanisms of Action
3.1 Substrates: The Raffinose Family of Oligosaccharides (RFOs)
The so-called raffinose family of oligosaccharides comprises raffinose (trisaccharide), stachyose (tetrasaccharide), and verbascose (pentasaccharide), all of which occur in the seeds of legumes, as well as in different parts of plants. Verbascose has three molecules of α-D-galactose attached to sucrose; stachyose has two, and raffinose one.
Alpha-galactosides are low-molecular-weight, non-reducing oligosaccharides and rank next to sucrose among abundant soluble sugars. These sugars constitute about 6–18% of the dry weight of mature legume seeds. Alpha-galactosides are sucrosylgalactosides and are characterized by the presence of an α(1→6) linkage between the galactosyl residue and the C-6 of the glucose moiety of sucrose.
RFOs participate in plant physiological processes like seed desiccation tolerance, seed germination, photosynthate translocation, and stress tolerance. However, in the human diet, food rich in RFOs causes stomach discomfort, flatulence, and diarrhea in humans and monogastric animals, as they lack α-galactosidase, a hydrolyzing enzyme needed for RFO breakdown.
Raffinose and stachyose are classified as antinutritional factors due to their high indigestibility by humans and other monogastric animals, whose intestinal mucosa does not secrete alpha-galactosidases.
3.2 Catalytic Mechanism (Digestive/Fungal Form)
At a molecular level, alpha-galactosidase works by cleaving alpha-galactosidic bonds in complex sugars. These bonds connect galactose molecules to other sugar molecules in oligosaccharides. The enzyme works by cleaving the alpha-1,6-galactosidic bonds in these complex carbohydrates, effectively breaking them down into simpler sugars that can be more easily absorbed by the body. This hydrolysis reaction is highly specific — alpha-galactosidase only works on certain types of bonds and sugars, which is why it is so effective for targeting the problematic oligosaccharides in beans and other gas-producing foods without interfering with other digestive processes.
When consumed as a supplement before meals containing oligosaccharides, alpha-galactosidase begins working in the digestive tract almost immediately. The enzyme travels through the stomach and into the small intestine, where it encounters complex sugars like raffinose, stachyose, and verbascose from food. As these food particles move through the digestive system, the enzyme breaks down the complex sugars into simpler components like galactose, sucrose, and glucose — sugars that the body can easily absorb. This prevents these undigested carbohydrates from reaching the large intestine where they would normally be fermented by bacteria, producing gas and causing discomfort.
3.3 Catalytic Mechanism (Human Lysosomal Form, α-GAL A)
The enzyme α-galactosidase (α-GAL, also known as α-GAL A; E.C. 3.2.1.22) is responsible for the breakdown of α-galactosides in the lysosome. Defects in human α-GAL lead to the development of Fabry disease, a lysosomal storage disorder characterized by the buildup of α-galactosylated substrates in the tissues.
Human α-Gal A is a lysosomal enzyme, meaning it functions within lysosomes, the "recycling centers" of cells. Its role is to break down specific glycosphingolipids, particularly globotriaosylceramide (Gb3), into ceramide and galactose. This process is vital for cellular health, preventing the accumulation of Gb3.
Alpha-galactosidase A bearing a mannose-6-phosphate marker binds to the mannose-6-phosphate receptor in the trans-Golgi network, is packed into clathrin-coated vesicles, and transported to endosomes. Due to the low pH in this cellular compartment, the receptor–ligand complexes dissociate and α-galactosidase A is delivered to lysosomes.
3.4 Absence in the Human Small Intestine
Mammals are deficient in intestinal α-galactosidase production and, consequently, are incapable of decomposing ingested α-galactosides by themselves. Instead, ingested α-galactosides are decomposed by microorganisms present in the intestine. This microbial decomposition normally results in flatulence and further confers a digestive discomfort to the mammal upon ingestion of α-galactoside-containing food or feed.
4. Scientific Evidence by Area of Use
4.1 Reduction of Intestinal Gas and Bloating in Healthy Adults
The most extensively studied application of supplemental alpha-galactosidase is the reduction of gas-related symptoms following ingestion of oligosaccharide-rich foods.
Key study (Di Stefano et al., 2007, Digestive Diseases and Sciences): In a randomized double-blind placebo-controlled protocol, the effect of alpha-galactosidase administration was evaluated on intestinal gas production and gas-related symptoms after a challenge test meal in healthy volunteers. Eight healthy volunteers ingested 300 or 1200 GalU of alpha-galactosidase or placebo during a test meal containing 420 g of cooked beans. Breath hydrogen excretion and occurrence of bloating, abdominal pain, discomfort, flatulence, and diarrhea were measured for 8 hours. The administration of 1200 GalU of alpha-galactosidase induced a significant reduction of both breath hydrogen excretion and severity of flatulence.
Two clinical trials involving small sample sizes (19 and 8 persons, respectively) showed that the over-the-counter product Beano, which contains α-galactosidase, reduced flatus frequency in normal persons following the ingestion of beans.
Limitation: The primary adult studies in healthy volunteers involve very small sample sizes (8–19 participants), limiting the statistical power and generalizability of the results.
4.2 Gas-Related Symptoms in Children (Pediatric Population)
Key study (Di Nardo et al., 2013, BMC Gastroenterology): A single-center, randomized, double-blind, placebo-controlled, parallel-group study was performed in a tertiary care setting. Fifty-two pediatric patients (32 female, age range 4–17) with chronic or recurrent gas-related symptoms were randomized to receive placebo (n=25) or α-galactosidase (n=27). The digestive enzyme decreased the number of days with moderate to severe bloating (p=0.03) and the proportion of patients with flatulence (p=0.02). No significant differences were found for abdominal spasms and abdominal distension. No adverse events were reported during treatment.
Although larger and longer trials are needed to confirm this result, α-galactosidase seems to be a safe, well-tolerated, and effective treatment for gas-related symptoms in the pediatric population.
Both treatments were given as drops or tablets, according to body weight, for 2 weeks. The primary endpoint was the reduction in global distress measured by the Faces Pain Scale-Revised (FPS-R) at the end of treatment compared to baseline.
Limitation: Single center; relatively small sample; 2-week duration may not reflect long-term outcomes.
4.3 Alpha-Galactosidase in Irritable Bowel Syndrome (IBS)
Evidence for alpha-galactosidase supplementation specifically in IBS patients is mixed and, in the higher-quality studies, does not demonstrate significant benefit.
Key study (Böhn et al., 2021, Neurogastroenterology & Motility): A randomized, double-blind crossover study examined 1200 GalU/meal α-galactosidase (Nogasin®) or placebo capsules on GI symptoms in patients with IBS after three standardized meals high in oligosaccharides. Twenty adult patients with IBS (19 females, mean age 49 years) were included. The enzyme α-galactosidase was not superior to placebo in reducing postprandial gastrointestinal symptoms after ingestion of provoking meals in IBS patients.
Key study (Hillilä et al., 2015, Scandinavian Journal of Gastroenterology): Abdominal bloating is reported by a majority of IBS patients. Excess colonic fermentation may cause gaseous symptoms. Several foodstuffs contain oligosaccharides with an α-galactosidic linkage that is resistant to mammalian hydrolases. Assisted hydrolysis by exogenous α-galactosidase enzyme could offer a way of controlling IBS symptoms by reducing colonic fermentation and gas production. The aim of this study was to assess the effect of AG on symptom severity and quality of life in IBS patients with abdominal bloating or flatulence. A total of 125 subjects with IBS received AG or placebo at meals for 12 weeks. AG showed a trend toward a more prominent decrease in IBS-SSS. The authors found no evidence to support the use of AG routinely in IBS patients. Improvement of clinical response at 4-week follow-up may suggest a long-term effect of unknown mechanism, but could also be attributed to non-responder drop out. Gastrointestinal side effects may be a coincidence in this study, but irritation of the GI tract by AG administration cannot be excluded.
A separate smaller trial reported a different finding: Patients were randomly assigned to one of two groups of 62 patients each; the first received a dose of 400 GalU of α-galactosidase 3 times a day and the second a placebo 3 times a day. A reduction in the IBS-Symptom Severity Score was observed in both groups: 67 points in the group treated with α-galactosidase and 47.2 points in the placebo group. The percentage of patients who responded positively to the therapy was significantly higher (p=0.028) in the group treated with α-galactosidase compared to the placebo group 4 weeks after the treatment.
Overall assessment: Evidence for alpha-galactosidase in IBS is currently inconsistent. The largest and best-powered RCT (125 subjects, 12 weeks) found no statistically significant benefit over placebo for routine IBS management, while smaller trials have reported positive signals. The evidence base is preliminary and insufficient to support a definitive recommendation for IBS.
4.4 Food Processing Applications: Soy and Legume Products
The consumption of soybean products has become more tolerable due to alpha-galactosidases. To avoid gastrointestinal disorders, alpha-galactosidases can be applied during processing to eliminate these oligosaccharides, or they can be administered orally to enhance food digestion. These enzymes can also be employed in the sugar industry to improve sucrose crystallization through the hydrolysis of raffinose from sugar beet and to increase the process yield.
4.5 Alpha-Galactosidase A and Fabry Disease
This section concerns the human lysosomal form of the enzyme (α-GAL A), not the dietary supplement. It is included for completeness given the shared enzyme nomenclature.
Fabry disease is an inherited lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. This enzyme deficiency results in the accumulation of glycosphingolipids found in the lysosomes of most cell types and tissues, manifesting as a multisystem disease.
Fabry disease is a lysosomal storage disease caused by mutations in the gene for the α-galactosidase A (GLA) enzyme. The absence of the enzyme or its activity results in the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in different tissues, leading to a wide range of clinical manifestations. More than 1000 natural variants have been described in the GLA gene, most of them affecting proper protein folding and enzymatic activity. Currently, FD is treated by enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT).
Two formulations of recombinant human GLA have been developed: alpha agalsidase (Replagal, by Shire) and beta agalsidase (Fabrazyme, by Sanofi Genzyme). The accumulation of clinical trial and real-world evidence over the last 20 years has shown that enzyme replacement therapy via lifelong intravenous infusions of gene-activated agalsidase alfa or recombinant agalsidase beta every other week is safe and clinically and biologically effective in patients with FD.
There are currently two treatment options for Fabry disease: recombinant enzyme replacement therapy (approved in the United States in 2003) and pharmacological chaperone therapy.
Important distinction: The recombinant enzyme therapies for Fabry disease are prescription pharmaceutical agents administered intravenously. They are categorically distinct from over-the-counter dietary supplements containing fungal alpha-galactosidase. They should not be conflated.
5. Body Systems and Health Areas Associated with Alpha-Galactosidase
5.1 Gastrointestinal System
The primary role of alpha-galactosidase in digestion is to prevent the fermentation of specific oligosaccharides in the large intestine. These oligosaccharides, often referred to as FODMAPs or specifically as galacto-oligosaccharides (GOS), are found in legumes, cruciferous vegetables, certain grains, and other vegetables. This process reduces fermentation by gut bacteria, which helps prevent the gas production that often accompanies the consumption of these foods.
5.2 Cardiovascular, Renal, and Nervous Systems (via Fabry Disease Context)
Reduced activity or deficiency of alpha-galactosidase A (AGAL) leads to escalating storage of intracellular globotriaosylceramide (GL-3) in numerous organs, including the kidneys, heart, and nervous system. Fabry disease is caused by a deficiency of α-galactosidase A leading to the lysosomal accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids; Fabry patients experience significant damage to the heart, kidney, and blood vessels that can be fatal. These systemic effects are relevant only in the context of the inherited enzyme deficiency (Fabry disease), not to the dietary supplement.
5.3 Carbohydrate Metabolism and Blood Glucose
A clinically relevant interaction involves blood sugar. Alpha-galactosidase converts some sucrose into glucose. This can affect blood sugar level. This is because among the products of RFO hydrolysis is sucrose, and the enzyme can also have secondary hydrolytic effects on sucrose itself, releasing free glucose. This is of specific relevance for individuals with diabetes or impaired glucose tolerance who monitor postprandial glycemia.
6. Dosage Forms and Dosages Reported in Clinical Studies
Alpha-galactosidase activity is measured in GalU (galactosidase units). The following dosages have been specifically reported in published studies and commercial formulations:
- In a randomized double-blind placebo-controlled study, healthy volunteers ingested 300 or 1200 GalU of alpha-galactosidase with a test meal containing 420 g of cooked beans. Only the 1200 GalU dose produced significant results.
- In the IBS crossover study, the dose was 1200 GalU per meal (Nogasin®) or placebo capsules.
- In the 12-week IBS study, 125 subjects with IBS received AG or placebo at meals for 12 weeks. (The specific GalU dose was reported in associated references as 1200 GalU.)
- In another IBS study, the first group received a dose of 400 GalU of α-galactosidase 3 times a day.
- In the pediatric trial, the treatment was administered at the beginning of each meal 3 times a day for 2 weeks. Both treatments were given as drops or tablets, according to body weight.
- The standard Beano tablet form contains 150 GalU of alpha-galactosidase per tablet.
- Typical dosage in commercial products is 300–1000 GalU per meal, taken immediately before or during consumption of gas-producing foods.
The enzyme works optimally in the slightly acidic environment of the stomach and small intestine, with peak activity occurring at a pH range of approximately 4.5–6.5.
7. Safety Considerations and Interactions
7.1 General Tolerability
Alpha-galactosidase is generally well-tolerated with minimal side effects; rare mild gastrointestinal upset like nausea or diarrhea may occur at high doses. No serious adverse events have been reported in studies. Alpha-galactosidase is relatively large as a protein. As a result, it cannot pass through the intestinal wall or enter the bloodstream.
7.2 Allergic Reactions
Hypersensitivity is uncommon but possible, particularly for those allergic to mold or fungi, since most commercial alpha-galactosidase is derived from Aspergillus niger. Symptoms might include rash, itching, or, in rare cases, more severe allergic responses. If an individual is allergic to Aspergillus (the mold used to produce the enzyme), they may experience hives, itching, or swelling of the lips or tongue.
7.3 Blood Glucose Interaction
Alpha-galactosidase converts some sucrose into glucose, which can affect blood sugar level. This consideration is particularly relevant for individuals with diabetes who manage postprandial glucose levels, since the hydrolytic products of RFOs include absorbable simple sugars including glucose.
7.4 Contraindication: Galactosemia
Alpha-galactosidase is contraindicated in galactosemia, a rare disorder impairing galactose metabolism. Because one of the primary products released by alpha-galactosidase hydrolysis is free galactose, individuals with classical galactosemia — who cannot metabolize galactose — should avoid the supplement.
7.5 Gastrointestinal Safety Signal in IBS
In the largest IBS trial, gastrointestinal side effects were observed; while these may be a coincidence, irritation of the GI tract by AG administration cannot be excluded. This warrants caution in individuals with pre-existing GI conditions beyond simple dietary intolerance.
7.6 FDA and Regulatory Status
Alpha-galactosidase may support digestion. The FDA has not evaluated this supplement for any medical use. It is sold in the United States as a dietary supplement under DSHEA regulations. The fungal-derived enzyme from Aspergillus niger carries GRAS (Generally Recognized as Safe) status for food applications.
7.7 Distinction from Fabry Disease Therapies
Individuals with Fabry disease should exercise caution, as dietary supplements differ fundamentally from the prescribed enzyme replacement therapies used for that condition. The pharmaceutical ERT products (agalsidase alfa and beta) are intravenously administered recombinant human proteins, entirely distinct from orally consumed fungal-derived dietary enzyme supplements.
8. Summary of Evidence Strength
- Reduction of gas/flatulence in healthy adults after legume consumption: Supported by multiple small RCTs; evidence is consistent but limited by very small sample sizes. The overall signal is positive for acute use.
- Reduction of gas-related symptoms in children: Supported by one RCT (n=52); results are encouraging but require confirmation in larger, longer trials.
- Irritable Bowel Syndrome: Evidence is mixed. The largest and most rigorous RCT (n=125) found no benefit over placebo. Smaller trials show a positive signal. Current evidence does not support routine use specifically for IBS.
- Fabry disease (human α-GAL A): Strong, long-term clinical evidence supports enzyme replacement therapy with recombinant human α-galactosidase A for Fabry disease; this is a distinct pharmaceutical indication unrelated to dietary supplementation.
References
Volver